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Activation and Increased Expression of Adhesion Molecules on Peripheral 
Blood Lymphocytes Is a Mechanism for the Immediate Lymphocytopenia
After Administration of OKT3
By Saskia Buysmann, Frederike J. Bemelman, Peter Th.A. Schellekens, Yvette van Kooyk, Carl G. Figdor,
and ineke J.M. ten Berge
We investigated the mechanism by which antihuman CD3 
monoclonal antibodies of the isotypes lgG2a (eg, OKT3) and 
IgA (eg, 1XA) can induce the rapid disappearance of virtually 
all circulating T lymphocytes. We hypothesize that upregula- 
tion of adhesion molecules on the lymphocyte membrane 
contributes to this effect. However, this hypothesis is diffi­
cult to test, because of the inherent lymphocytopenia and/ 
or shifts in lymphocyte populations between intra and extra- 
vascular compartments. Therefore, studies in vitro were per­
formed, as well. Analysis of peripheral blood lymphocytes 
isolated at several times after addition of OKT3 or IXA to 
whole blood of healthy individuals showed an immediate 
increase in the proportion of T cells expressing NKI-L16, an 
activation epitope on CD11a/CD18. Likewise, an increase in
IT IS well-established that OKT3, a murine IgG2a mono­clonal antibody directed against the CD3 molecule on 
human T lymphocytes, is a potent immunosuppressive agent 
in prophylaxis and treatment of acute allograft rejection.1"3 
It is generally assumed that the concomitant immediate and 
profound peripheral blood lymphocytopenia4 is caused by 
sequestration of OKT3-sensitized T lymphocytes, following 
binding to Fc- and complement receptors.5'7 However, this 
cannot be the sole explanation, in particular for the initial 
phase of T lymphocytopenia. Indeed, previous studies with 
murine isotype switch variant CD3 monoclonal antibodies 
in chimpanzees, as well as humans, have shown that the 
IgG2a, as well as IgA isotypes, can induce an immediate, 
although transient, lymphocytopenia.8,9 Because neither 
chimpanzees nor humans express Fc receptors for murine 
IgA and monomeric IgA is generally assumed to have poor 
complement-activating capacity,9 the rapidly occurring 
lymphocytopenia induced by the anti-CD3 monoclonal anti­
bodies must have other causes. We hypothesize that binding 
to vascular endothelium via adhesion molecules is instru­
mental in the rapidly occurring peripheral lymphocytopenia.
In vivo, adhesion of peripheral blood lymphocytes to en­
dothelium is a multiple-stage process, starting with a low-
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CD11b/CD18 expression occurred. In parallel experiments, a 
transiently increased adhesion of T cells to endothelial cell 
monolayers was observed. This adhesion could be com­
pletely blocked by anti-CD18 or anti-CD11a monoclonal anti­
bodies and only partly by an anti-CDUb antibody. Our data 
indicate that upregulation of activation epitopes of CD11a/ 
CD18, as well as increased expression of CD11b/CD18 on T 
lymphocytes, may result in increased adhesion of these cells 
to intercellular adhesion molecule-1 (1CAM-1) and 1C AM-2 on 
vascular endothelium. This phenomenon may, at least, 
partly explain the rapidly occurring peripheral lymphocyto­
penia observed in vivo.
© 1996 by The American Society of Hematology.
avidity contact via CD62L (L-selectin) and resulting in the 
rolling of lymphocytes along the endothelial cell layer, thus 
facilitating the binding of activated integrins such as CD I la1 
CD18 (lymphocyte function associated antigen-1, LFA-1), 
CD1 lb/CD 18 (Mac-1), and CD49d/CD29 (very late antigen- 
4, VLA-4) to their respective ligands: intercellular adhesion 
molecule-1 and -2  (ICAM-1 and ICAM-2) and vascular cell 
adhesion molecule- 1 (VCAM-1). These interactions result 
in a high-avidity binding of lymphocytes to endothelium.10 
Likewise, incubation of T lymphocytes with anti-CD3 mono­
clonal antibodies in vitro has been shown to result in a 
transient high-avidity state of the CDlla/CD18 complex and 
an increased adhesion to ICAM-1-coated surfaces. This ef­
fect was maximal after 10 minutes and subsided within 30 
minutes to 2 hours.11 To test our hypothesis, we investigated 
in vivo, as well as in vitro, whether OKT3 induces not only 
an increase in the avidity of the CD 11 a/CD 18 complex, but 
also of other adhesion molecules on T lymphocytes. Thus, 
CD2 positive and CD3 positive peripheral blood lympho­
cytes were studied for their expression of CD62L, CD 11 a/ 
CD18, NKI-L16 (a Ca2+-dependent epitope on the CD1 la/ 
CD 18 complex, which is only expressed on activation) , 12,13 
CDllb/CD18, and CD49d/CD29. Time-course studies were 
performed just before and at frequent time intervals after 
administration of OKT3 to patients with acute kidney allo­
graft rejection. Unfortunately, we were unable to perform 
similar studies with IgG2a and IgA isotype switch variants of 
CD3 monoclonal antibodies, because such variant antibodies 
were not available for clinical use. A control group consisted 
of patients with acute kidney allograft rejection who were 
treated with high-dose methylprednisolone only.
Moreover, studies in vitro were performed in which pe­
ripheral blood lymphocytes were incubated at 37°C in the 
presence of OKT3 or the IgA isotype switch variant anti- 
CD3 antibody, after which the expression of adhesion mole­
cules was studied. Furthermore, we showed that an increased 
expression of adhesion molecules will result in an enhanced 
adhesion of T lymphocytes to endothelial cell monolayers. 
Finally, blocking studies were performed to identify the ad­
hesion molecule(s) that are responsible for this increased 
adhesion.
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MATERIALS AND METHODS
Methods
The study was approved by the institutional research and ethical 
committees of the Academic Medical Center of the University of 
Amsterdam. Written informed consent was obtained from all pa­
tients.
In Vivo Studies
Patients. Ten renal transplant recipients (three men, seven 
women, median age 31 years, range, 20 to 61 years) were studied. 
These patients were treated for 10 consecutive days with 5 mg/day 
OKT3 (Ortho Diagnostic Systems, Raritan, NJ) because of acute 
kidney allograft rejection, diagnosed on the basis of clinical manifes­
tations and confirmed by core biopsy. As recommended by the manu­
facturer, before OKT3 administration on day 1, a single dose of 500 
mg methylprednisolone was given. The control group consisted of
10 renal transplant recipients (four men, six women, median age 31 
years, range, 21 to 54 years) who were treated for acute rejection 
with methylprednisolone 500 mg/day for 6 consecutive days. Basic 
immunosuppressive therapy in both groups consisted of prednisolone 
(10 mg/day) and cyclosporin (dosage adjusted so as to result in 
whole-blood trough levels of 150 to 200 /ig/L).
Materials and methods. Peripheral blood was collected before 
the administration of 500 mg methylprednisolone and at 3, 10, 15,
30, 60, 120 minutes, 4.5, and 24 hours after administration of either 
5 mL (ie, 5 mg) OKT3 or 5 mL 0.9% saline (control group). At 
each time point, total leukocyte and differential counts were deter­
mined by flow cytometry (Technicon HI System; Bayer/Technicon, 
Tarrytown, NY) on blood anticoagulated with 0.38 mmol/L EDTA, 
Peripheral blood mononuclear cells were isolated by centrifugation 
of heparinized blood on Ficoll-Paque (density 1.076; Pharmacia, 
Uppsala, Sweden). Contaminating erythrocytes were Jysed by incu­
bation with ammoniumchloride (155 mmol/L NH4C1, 10 mmol/L 
KHCO3, 0.1 mmol/L EDTA, pH 7.4) for 10 minutes on ice, followed 
by two washings of the mononuclear cells in PBS-A (ie phosphate 
buffered saline (PBS) containing 0.5% wt/vol bovine serum albumin 
(Boseral DEM, Organon Teknika B.V., Boxtel, Holland) and 0,01% 
wt/vol sodium azide).
Immunofluorescence. Peripheral blood mononuclear cells were 
incubated for 30 minutes at 0°C in PBS-A with appropriate dilutions 
of the fluorescein isothiocyanate (FITC)-labeled monoclonal anti­
bodies CD 11a (Dako, Glostrup, Denmark, clone MHM24, IgGlk), 
NKI-L16'2,13 and CD 16 (Central Laboratory of the Netherlands Red 
Cross Blood Transfusion Service (CLB), Amsterdam, The Nether­
lands; clone CLB-149, IgG2a), and with the phycoerythrin-labeled 
monoclonal antibody CD! lb (Dako; clone 2LPM19c, IgGlk). For 
determination of CD62L and CD49d/CD29 expression, an indirect 
staining procedure was used consisting of primary incubation of 
the mononuclear cells with appropriate dilutions of the monoclonal 
antibodies LECAM-1 (directed against CD62L, Becton Dickinson, 
San Jose, CA; clone S K li ,  IgG2a, biotinylated) or CD49d (directed 
against VLA-o;4 chain, Immunotech, Marseille, France; clone HP2.1, 
IgGl), followed by incubation with phycoerythrin-labeled streptavi- 
din (Becton Dickinson) or FITC-labeled goat antimouse IgGl 
(Southern Biotechnology, Birmingham, AL), respectively. All sam­
ples were two-color stained with a phycoerythrin- or FITC-labeled 
anti-CD2 monoclonal antibody (Dako; clone MT910, IgGlk or Bec­
ton Dickinson, Leu-5b; clone S5.2, IgG2a, respectively) and with a 
phycoerythrin- or FITC-labeled anti-CD3 monoclonal antibody (both 
from Becton Dickinson, Leu-4; clone SK7, IgGl). Determination of 
the absolute number of CD3 positive cells was performed in two 
ways: (1) direct labeling with a phycoerythrin- or FITC-labeled anti- 
CD3 monoclonal antibody (Becton Dickinson, Leu-4; clone SK7, 
IgGl) and (2) with FITC labeled F(ab ')2 fragments of goat antimouse
Ig (GAM F(ab')2, obtained from the CLB. Analysis of cell suspen­
sions was performed on a FACS can (Becton Dickinson). Lympho­
cytes in the mononuclear cell population were gated on forward and 
side scatter.
In Vitro Studies
Immunofluorescence. A total of 55 mL heparinized peripheral 
blood was taken from five healthy individuals and kept in a 37°C 
waterbath. A 5-mL sample was set apart and the remaining 50 mL 
blood was divided into four separate portions, to which OKT3, IXA, 
an irrelevant murine monoclonal antibody of the IgG2a isotype (F23- 
49, directed against Mycobacterium tuberculosis14) or an irrelevant 
murine monoclonal antibody of the IgA isotype (clone TEPC15, 
mouse IgA/c myeloma protein; Sigma, St Louis, MO) was added, 
each at a final concentration of 1 /¿g/mL, which is comparable to 
serum levels after administration of 5 mg OKT3 in vivo.15 At 3, 30, 
and 60 minutes after addition of the monoclonal antibody, 3 mL 
samples were taken. Peripheral blood mononuclear cells were sepa­
rated by Ficoll-Paque density gradient centrifugation and expression 
of the same adhesion molecules as analyzed in the in vivo studies 
was measured on a FACScan as described above. At each time point, 
total leukocyte and differential counts were determined by flow cy­
tometry (Technicon HI System).
Functional Adhesion Studies
From eight healthy individuals, 40 mL heparinized peripheral 
blood was taken. Mononuclear cells were isolated by cenLrifugation 
on Ficoll-Paque, followed by three washings in Tris-buffered Earle’s 
Balanced Salt Solution containing 5% fetal calf serum. Next, CD3+ 
T cells were obtained by a negative selection procedure: removal of 
B lymphocytes, monocytes, and natural killer cells by incubation 
with murine monoclonal antibodies anti-CD19 (CLB, clone 11G1), 
anti-CD 14 (CLB, clone 8G3), and anti-CD16 (CLB, gran-1) fol­
lowed by incubation with sheep antimouse IgG coated Dynabeads 
(Dynal A.S, N-0212, Oslo, Norway). This procedure resulted in 
>95% pure T-cell suspensions as confirmed by fluorescence-acti- 
vated cell sorter (FACS) analysis after staining the cells with a 
mixture of FITC-labeled CD3- and phycoerythrin-labeled CD 16 and 
CD56 monoclonal antibodies (NK-Simulset, Becton Dickinson). The 
CD3-positive cells (2 X 106 cells/mL) were incubated on ice for 30 
minutes with OKT3, IXA, the irrelevant IgG2a monoclonal antibody 
F23-49, or the irrelevant IgA monoclonal autibody TEPC15, each 
at a final concentration of 1 /¿g/mL, followed by two washings at 
4°C with Iscove’s modified Dulbecco’s medium containing 5% fetal 
calf serum. Next, 2  ¿¿g/mL goat antimouse Ig (GM17D, CLB) was 
added to cross-link the T-cell receptor/CD3 complexes, immediately 
followed by 3 minutes 10# centrifugation at 37°C.11 Part of the cell 
suspension was then added to a cell monolayer consisting of an 
immortalized endothelial cell line derived from human umbilical 
vein endothelial cells,16 cultured in 96-well plates (Nunclon Micro 
Well F96, Nunc A.S, Roskilde, Denmark) on \% gelatin (Sigma, 
G1S90) in PBS. The remaining cell suspension was placed in a 
shaking waterbath at 37°C and after 30 and 60 minutes of incubation, 
samples were added to the endothelial cell monolayers. The 96-well 
plates were incubated for 15 minutes at 37°C in 5% C 0 2, followed 
by removal of the nonadherent fraction by washing three times with 
200 f£L 37°C Earle’s Balanced Salt Solution containing 5% fetal 
calf serum. The adherent fraction was stained with Diff Quick (a 3- 
step staining procedure comprising: ( 1 ) fixation in methanol with 
fast green 0.002 g/L, (2) eosin G in phosphate buffer pH 6,6, and 
(3) thiazine dye in phosphate buffer pH 6.6 (Baxter Dade A.G, 
Diidingen, Switzerland). All experiments were performed in tripli­
cate. As a positive control, the cells were preincubated with phorbol 
myristate acetate (50 ng/mL, Sigma) instead of a CD3 monoclonal
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antibody. Blocking studies were performed with monoclonal anti­
bodies directed against the common /?2 integrin chain (CD 18): TS 
1/18,17 against C D lla  (NKI-L7),18 and against C D llb  (Bear-1 19), 
added to the endothelial cell monolayer together with the T cells. 
The final antibody concentration was 10 /xg/mL, which in previous 
studies was shown to result in a maximal inhibition of adhesion. 
The adhesion was scored blindly at 200 X magnification by three 
investigators independently, in a semiquantitative way: 0 — no T 
cells, 1 *  <50 T cells/field, 2 *  50 to 100 T  cells/field, 3 = 100 
to 250 T cells/field, 4 =  250 to 350 T cells/field, 5 =  >350 T cells/
field.
Because it is difficult to estimate the extent to which cross-linking 
occurs in vivo, since we do not know which part of the administered 
amount of CD3 monoclonal antibody actually binds to the T cells 
and which part remains unbound, both the whole blood incubation 
and adhesion studies were performed with concentrations of OKT3 
or IXA ranging from 0.01 to 10 jxgJmL, To exclude the possibility 
that the expression and functional activity of adhesion molecules was 
influenced by any antibody not directed to the CD3/T~cell receptor 
complex, whole blood incubations and adhesion studies were also 
performed with murine IgG2a monoclonal antibodies directed 
against either the CD4 molecule (ie> CLB-T4), or a major histocom­
patibility complex (MHC) class-I antigen (W6/32), instead of the 
CD3 monoclonal antibody. Both the CD4 and the MHC class-I 
monoclonal antibody were tested at concentrations of 0 .1 , 1 , and 10 
(iglm h .
Calculations and Statistics
Absolute number o f double-positive cells. This was determined 
by the percentage of double-positive cells (calculated by means of 
PCLYSYS software from Bee ton Dickinson) multiplied by the abso­
lute number of lymphocytes at the same time point. All values are 
expressed as mean ±  standard error of mean (SEM).
Mean fluorescence intensity (MFI). At all time points the MFI 
was calculated by means of PCLYSYS software. A total of 100% 
represents the MFI values obtained from the blood samples before 
the start of treatment. The values obtained several times after admin­
istration of OKT3 are represented as a percentage of the pretreatment 
value. All values are expressed as mean ±  SEM.
Statistical analysis, Differences within groups were tested by 
Wilcoxon Test for Matched pairs. A probability (P) value <  .05 
was considered to indicate a significant difference.
2.00 r
RESULTS
In Vivo Studies
Effect of OKT3 administration on peripheral T lympho­
cytes. As seen in Fig 1, treatment with 5 mg OKT3 caused 
within 3 minutes in all of the 10 patients studied a sharp 
decline in the number of CD3* peripheral blood lymphocytes 
(from 1.24 ±  0.15 X  107L to 0.07 ±  0.01 X  107L, P <  
.05). From 3 minutes on, the number of goat antimouse 
F(ab')2 positive cells decreased in parallel, while the number 
of CD3+ cells remained very low during the whole study 
period. Likewise, the absolute number of CD2‘f‘ peripheral 
blood lymphocytes showed within 3 minutes a rapid decrease 
from 1.40 ±  0.16 X  109/L to 0.54 ±  0.06 X 109/L (P <  
.05). Afterwards, the decrease in CD2 + lymphocytes was 
more gradual, until a lowest value of 0.08 ±  0.01 X 109/L 
was reached, persisting for at least 4.5 hours. Only a partial 
recovery to 0.29 ±  0.11 X  109/L was observed after 24 hours 
(ie, immediately before administration of the second OKT3 
dose).
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Fig 1. Absolute numbers of CD2+ and CD3+ lymphocytes on ad­
ministration of 5 mg OKT3 or 500 mg methylprednisolone. Results 
are given as mean ± SEM in each group (n = 10). (O), number of 
CD2+ cells following OKT3; {•), number of CD3+ cells following OKT3; 
(□), number of CD2+ cells following methylprednisolone; {■), number 
of CD3k1 cells following methylprednisolone,
Effect o f  OKT3 administration on the expression of adhe­
sion molecules on peripheral blood lymphocytes, Data ob­
tained before and at 3, 10, 60, 120 minutes, and 24 hours 
after administration of the first dose of OKT3 are summa­
rized in Table 1. The MFI of CD62L on the remaining CD3 
positive cells decreased within 120 minutes to 52.41 ±  
12.86% of pretreatment value (P <  .05). The MFI of CD1 la 
on the remaining CD2 positive cells showed a 2.5~fold in­
crease after 3 minutes and remained high for the whole study 
period, while the MFI of C D lla  on the remaining CD3 
positive cells increased much less. The MFI of NKI-L16 on 
the remaining CD3 positive cells showed hardly any change 
(Table 1). Before OKT3 administration, 22.86 ± 4.39% of 
the CD2 positive and 18.55 ± 3.71% of the CD3 positive 
lymphocytes were C D llb  positive. However, from 10 
minutes after OKT3 administration, almost all the remain­
ing CD2+CD3“ cells were C D llb  positive, and these 
CDi lb+CD2H' cells followed the total number of CD2 posi­
tive lymphocytes. These remaining C D llb +CD2+CD3~ ap­
peared to be also CD 16 positive (data not shown), a pheno­
type characteristic for natural killer cells. The MFI of CD 1 lb 
on the remaining CD2 positive cells showed a 1 .8 -fold in­
crease within 3 minutes following administration of OKT3 
and remained high for the whole study period. The MFI of 
C D llb  on the remaining CD3 positive cells also showed a 
1.9-fold increase within 10 minutes and remained elevated 
for at least 4.5 hours. No changes were observed in the 
percentage of CD49d positive cells or in the MFI of CD49d 
on the remaining CD2 positive and CD3 positive population 
after administration of OKT3 (data not shown).
In the 10 patients from the control group (treated with 
500 mg methylprednisolone only), the absolute numbers of 
CD2+ peripheral blood lymphocytes initially increased from
Table 1. Expression of Adhésion Molecules on CD3 Positive and CD2 Positive Cells After Administration of 5 mg OKT3
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Time (min) CD3+ CD62L+CD3' CD11a+CD3+ [NK1-L16]+CD3+ CD'l1b+CD3-f
0 abs. no. 1,24 ± 0.15 1.06 ± 0.19* 1.30 ±  0.22 0.40 ±  0.07 0.23 ±  0.05
MFI 100.00 ± 0.00 100.00 ±  0.00 100.00 ±  0.00 100.00 ±  0.00
3 abs. no. 0.07 ±  0.01 0.07 ± 0.01 0.10 ±  0.02 0.07 ±  0.01 0.04 ±  0.004
MFI 89.49 ± 17.77t 137.48 ±  6.28 108.01 ±  2.92 168.60 ±  12.35
10 abs. no. 0.03 ±  0.01 0.05 ± 0.01 0.06 ±  0.01 0.04 ±  0.01 0.02 ±  0.003
MFI 86.15 ±  17.70 145.33 ±  10,71 111.55 ±  5.04 187.27 ±  18.87
60 abs. no. 0.02 ±  0.01 0.02 ±  0.01 0.04 ±  0.02 0.01 + 0.002 0.01 ±  0.01
MFI 76,26 ± 11.87 133.30 ±  10.89 116.11 ± 9.75 227.61 ±  33.72
120 abs. no. 0.01 ±  0.004 0.01 ± 0.001 0.01 ±  0.004 0.01 ±  0.003 0.01 ±  0.004
MFI 52,41 ± 12.86 121.81 ±  13.90 122,30 ± 7.05 196.33 ±  24.26
24 h abs. no. 0.11 ±  0.03 0,07 ± 0.06 0.16 ±  0.09 0.01 ± 0.002 0.03 ±  0.01
MFI ND ND ND ND
Time (min) CD2+ CD62L+CD2+ CD11a+CD2+ [NKI-L16]+CD2+ CD11b+CD2+
0 abs. no. 1.40 ± 0.16 1.06 ± 0.19 1.40 ±  0.16 0.47 ±  0.05 0.32 ±  0.03
MFI 100.00 ±  0.00 100.00 ±  0.00 100.00 ±  0.00 100.00 ±  0.00
3 abs. no. 0.54 ± 0-06 0,20 ±  0.04 0.55 ±  0.06 0.52 ±  0.06 0.48 ±  0.05
MFI 74.53 -J: 4.98 241,76 ±  20.21 125.75 ±  11.75 179.70 ±  18.62
10 abs. no. 0.34 ± 0.07 0.11 ±  0.03 0.34 ±  0.07 0.30 ±  0.08 0.31 ±  0.07
MFI 69.61 ±  3.98 252.68 ±  22.25 126.42 ± 15.80 169.37 ±  17.55
60 abs. no. 0.13 ± 0.03 0.06 ±  0.05 0.20 ±  0.08 0.20 ± 0.08 0.18 ±  0.08
MFI 69.93 ±  7.39 255.57 ±  24.16 125.57 ±  16.70 174.02 ±  18.59
120 abs. no. 0.09 ± 0.02 0.01 ±  0.003 0.09 ±  0.02 0.11 ±  0.02 0.08 ±  0.02
MFI 75.32 ±  13.08 218.26 ±  16.67 123.71 ± 16.88 157.55 ±  20.28
24 h abs. no. 0.29 ± 0.11 0.15 ±  0.06 0.30 ±  0.11 0.16 ±  0.07 0.18 ±  0.07
MFI 107.91 ±  16.52 176.44 ±  10.14 136.21 ±  27.14 155.15 ±  36.95
All values represent mean ± SEM (n = 10).
Abbreviation: abs. no., absolute number; ND, not determined. 
* x 109/L.
t  Percent of pretreatment value.
1.53 ± 0.23 X 109/L before drug administration to 1.85 ±  
0.20 X 109/L at 10 minutes thereafter. From 15 minutes 
onwards, the CD2+ cell counts showed a gradual decrease 
to 0.45 ± 0.02 X 109/L after 4.5 hours. After 24 hours, they 
had almost completely recovered to 1.35 ± 0.17 X 109/L 
(Fig 1). The absolute number of CD3 positive cells remained 
constant during the first 15 minutes and then decreased and 
recovered parallel with the CD2 positive cells (Fig 1). No 
changes in the expression of the adhesion molecules CD62L, 
CDlla/CD18, NKI-L16, and CD49d/CD29 were observed 
from 15 minutes onwards, neither on CD2 positive nor on 
CD3 positive cells (data not shown). However the absolute 
number of CDl'lb+CD2+ cells increased, from 0.51 ± 0.06 
X 109/L before drug administration to 1.02 ±  0.09 X 109/L 
at 10 minutes after saline administration, while the absolute 
number of CD1 lb+CD3+ cells remained constant during this 
time interval. The MF1 of C D !lb on the remaining CD2 
positive and CD3 positive cells showed hardly any change 
(data not shown).
In Vitro Studies
Effect of OKT3 on the expression of adhesion molecules 
on peripheral lymphocytes. Addition of 1 fig/mL OKT3 or 
IXA to heparinized blood from five healthy volunteers did 
not induce any change in the absolute numbers of CD2+ 
cells, CD3+ cells, and CD16+CD56+CD3" (natural killer)
cells and neither did the expression of the adhesion mole­
cules CD62L, CD1 la/CD18, and CD49d/CD29 on CD2 pos­
itive and CD3 positive lymphocytes change (data not 
shown). In contrast, the number of CD3 positive lympho­
cytes expressing the activation epitope NKI-L16 on the 
CDlla7CD18 complex, showed a twofold increase within 3 
minutes after addition of 1 pg/m L  OKT3 (Fig 2A), followed 
by a gradual decrease. Addition of 1 /ig/mL IXA also in­
duced a twofold increase in the number of CD3 positive 
lymphocytes expressing the NKI-L16 epitope on the CD1 la / 
CD 18 complex, although more slowly as compared with 
OKT3 (Fig 2 B). No changes were detected in the absolute 
numbers of C D lIa+CD3~'' cells (Fig 2 A and B), nor in MFI 
of NKI-L16 and CD1 la, either after OKT3 or IXA (data not 
shown). In addition, an immediate increase in MFI of CD1 lb  
on CD3 positive lymphocytes was observed on incubation 
with either OKT3 or IXA, reaching a maximum at three 
times the preaddition value after 60 minutes incubation (Fig 
3A and B). Both the increase in NKI-L16 and CD1 lb  expres­
sion were dose dependent, reaching a maximal effect with
10 (jig/mL for OKT3 and with 1 /zg/mL for IXA. A total of 
0,1 /jg/mL OKT3 or IXA still induced an increased expres­
sion of both adhesion molecules, but less than that observed 
with 1 /ig/mL o f each monoclonal antibody, and with 0.01 
(iglmL OKT3 or IXA, no changes in adhesion molecule 
expression were detectable (data not shown). No changes
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Fig 2. (A) Absolute numbers of [NKf-L16J+CD3+ and CD11a+CD3+ 
lymphocytes after addition of 1 ftg/m L OKT3 or 1 f ig/mL of an irrele­
vant murine lgG2a monoclonal antibody to whole blood samples of 
five healthy individuals. (B) Similar data after addition of 1 /ig/mL  
IXA or 1 /xg/mL of an irrelevant murine IgA monoclonal antibody. 
Results are given as mean ±  SEM. Open bars, numbers of [NKI- 
L16]+CD3+ cells after irrelevant isotype control antibodies; solid bars, 
number of [NKI-Ll6]+CD3+ cells after OKT3 (A) or IXA (B); cross- 
hatched bars, number of CD1la+CD3* cells after OKT3 (A) or IXA (B).
occurred in the expression of NKI-L16 or C D llb  on CD3 
positive cells in control samples incubated with murine 
IgG2a monoclonal antibodies directed against either the CD4 
molecule or against a MHC class-I antigen, in any concentra­
tion tested (data not shown). Irrelevant murine monoclonal 
antibodies of the IgG2a or IgA isotype did not induce any 
alterations in expression of these adhesion molecules (data 
not shown).
Functional adhesion studies. Functional adhesion stud­
ies were performed to test whether the increase in expression 
of NKI-L16 and CD 1 lb/CD 18 after incubation with OKT3 
or IXA affected the adhesion capacity of the T cells. Indeed, 
incubation of purified T cells with 1 ¿¿g/mL OKT3 or IXA 
in vitro caused a transient increase in adhesiveness of these
cells to endothelial cell monolayers. Figure 4A demonstrates 
that after 3 minutes incubation of OKT3-coated T cells with 
goat antimouse Ig at 37°C, an adhesion score of 4.15 ± 0.22 
was reached. Three minutes incubation of IXA-coated T 
cells with goat antimouse Ig at 37°C resulted in an adhesion 
score of 3.11 ± 0 .2 6 . The increased adhesiveness appeared 
to be transient, because after 30 or 60 minutes incubation, the 
adhesion scores decreased markedly (Fig 4A). Dose response 
curves showed that maximal adhesion of T cells to endothe­
lium was observed with a concentration of 1 ¿¿g/mL of either 
OKT3 or IXA. A  total of 0.1 ¿/g/mL OKT3 or IXA could 
still induce T-cell adhesion to endothelium, but less than 
that observed with 1 ¿¿g/mL of each monoclonal antibody, 
while with 0.01 ¿¿g/mL OKT3 or IXA, no changes in adhe­
sion could be detected (data not shown). As a positive con-
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Blocking of anti-CD3 monoclonal antibody-induced adhesion of puri­
fied T cells to endothelial cell monolayers with the monoclonal anti­
bodies NKI-L7, Bear-1, and TS 1/18, directed against the a  chain of 
the CD11a/CD18 complex, the a  chain of the CDl1b/CDl8 molecule, 
and the common /3Z integrin (CD18), respectively. Results are given 
as mean ± SEM. Open bars, 1 /¿g/mL OKT3; solid bars, 1 yxg/mL IXA. 
Adhesion score 0, no T cells adherent to endothelium; 1, <  SOT cells/ 
field; 2, 50 to 100 T cells/field; 3, 100 to 250 T cells/field; 4, 250 
to 350 T cells/field; 5, >350 T cells/field, scored independently at a 
magnification of 200 x by three technicians.
trol, T lymphocytes were incubated with 50 ng/mL phorbol 
myristate acetate. This resulted in an adhesion score of 4.67 
±  0,37. As a negative control, T cells were incubated with 
murine IgG2a monoclonal antibodies directed against either 
CD4 or a MHC class-I antigen. No changes in adhesion 
score were observed in any of the concentrations tested (not 
shown). Irrelevant murine monoclonal antibodies of the 
IgG2a or IgA isotype did not induce any alterations in adhe­
sion score (Fig 4A).
The theoretical possibility that circulating human anti­
mouse antibodies, which could be present in serum and can 
bind to the CD3 monoclonal antibody on one site and with 
Fc receptors on the other site, was excluded because the 
presence of human antimouse antibodies could not be de­
tected by FACS analysis after incubating CD3 monoclonal
antibody-coated cells with human autologous serum (data 
not shown).
Blocking studies showed that coincubation of OKT3- or 
IXA-coated T lymphocytes with either a CD 18 or a C D !la  
monoclonal antibody completely inhibited the increased ad­
hesion as observed after 3 minutes incubation with goat 
antimouse Ig (Fig 4B). Co incubation with a'CD l ib  mono­
clonal antibody resulted in partial inhibition (Fig 4B).
DISCUSSION
In line with previous reports, the present study demon­
strates that administration o f the murine IgG2 a antibody
i
OKT3 causes an immediate peripheral T lymphocytopenia. 
Studies as to the causative mechanism(s) of this initial rapid 
disappearance of CD2+CD3+ lymphocytes are hampered by 
this very same phenomenon, because cells are no longer 
available for functional studies ex vivo. The decrease in the 
expression of CD62L on CD3+ T lymphocytes may reflect 
activation, leading to shedding of CD62L from the cell sur­
face .20’21 Alternatively, it could reflect a preferential disap­
pearance from the peripheral blood compartment of T cells 
with high CD62L expression. The latter possibility is sup­
ported by our observation that in the experiments in vitro, 
no change in expression of CD62L on T cells occurred. The 
increase in the percentage of CDllb* and CD16+ cells 
within the remaining CD2+CD3~ population suggests that 
the observed increase in expression (MFI) of C D lla  and 
CD1 lb and the decrease in MFI of CD62L on the remaining 
CD2+CD3" lymphocytes results from a selective enrichment 
in the peripheral blood compartment of natural killer cells, 
which are indeed known to have a higher CD 1 la and CD 1 lb 
expression,22 (unpublished results), as well as a lower 
CD62L expression21 as compared with T lymphocytes. The 
increase in MFI of C D llb  on the remaining CD3 positive 
lymphocytes might reflect an actual upregulation of this ad­
hesion molecule, as was already described by Muto et al.22 
These investigators showed that 30 minutes stimulation of 
T cells with 10 ng/mL phorbol myristate acetate at 37°C 
resulted in a twofold increase in the MFI of C D llb  on T 
cells, as well as a twofold increase in the percentage of T 
cells expressing C D llb . This increased C D llb  expression 
on T cells could not be blocked by cycloheximide, sug­
gesting the presence o f  cytoplasmic (granule) stores of 
CDl lb in the T cells. Phorbol myristate acetate is a direct 
activator of protein kinase C. Activation of T cells via the 
T-cell receptor/CD3 complex can also stimulate the inositol 
phospholipid mechanism, thereby giving rise to activation 
of protein kinase C ,12 which, in turn, may result in a rapid 
increase in C D llb  expression.
To discriminate between the two possibilities of either 
redistribution o f cells between peripheral blood and other 
lymphoid compartments or real upregulation of adhesion 
molecules, the expression of these adhesion molecules was 
also measured on peripheral blood lymphocytes in vitro at 
various time points after addition of OKT3, as well as IXA, 
to whole blood of healthy control individuals. If IgA antibod­
ies can indeed cause an upregulation of adhesion molecules, 
this could explain the immediate peripheral blood lymphocy­
topenia that occurs after in vivo administration of a CD3
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monoclonal antibody of the IgA class,9 despite the absence 
of Fc receptors for murine IgA in humans and the inability 
of murine IgA to activate human complement.
In contrast to the results obtained from the studies with 
OKT3 in vivo, no change in expression of GDI la was ob­
served in vitro, although an immediate, marked increase was 
observed in the absolute numbers of NKI-L16 positive T 
cells after addition of either OKT3 or IXA. Because the 
monoclonal antibody NKI-L16 recognizes a Ca2+-dependent 
activation epitope on the C D lla/C D 18 complex, its expres­
sion can be used as a parameter for an activation state of 
this adhesion molecule. However, it is known that expression 
of the NKI-L16 epitope by itself is not sufficient for cell­
cell adhesion. Only after specific triggering of a lymphocyte 
by CD3 monoclonal antibodies through the T-cell receptor/ 
CD3 complex, the NKI-L16 epitope becomes capable of 
high-affinity ligand binding. 12,13 Thus, the increased expres­
sion of this activation epitope, as demonstrated in the present 
study, may quite well play a role in the mechanism underly­
ing the rapid decrease of CD1 la +[NKI-L16]'! CD2+CD3 
cells in the peripheral blood compartment after OKT ad­
ministration, as these cells will strongly adhere to ICAM-1 
and ICAM-2 on vascular endothelium. In contrast, C D lia + 
[NKI-L16]+CD2+CD3~ cells would remain in the circula­
tion, not being activated via the T-cell receptor/CD3 com­
plex, which is a prerequisite for induction of the high-avidity 
state of the CD 11.a/CD 18 molecule. The observed increase 
in expression of C D l  lb on CD3-positive lymphocytes after 
the addition of either OKT3 or IXA in vitro is compatible 
with our findings in vivo after administration of 5 mg OKT3 
and may play an additional role in adhesion of T lympho­
cytes to ICAM-1 on vascular endothelium.
Indeed, incubation of T lymphocytes with either OKT3 
or IXA appeared to induce an increased, transient adhesive­
ness of these cells to endothelial cell monolayers within 3 
minutes. Because this increase was completely inhibited in 
the presence of C D l la or C D l8 monoclonal antibodies, and 
partly in the presence of a C D l lb monoclonal antibody, 
the induced activation status of the CD 11 a/CD 18 molecule 
appears to be an absolute prerequisite for the immediate 
adhesion of T cells to vascular endothelium as induced by 
CD3 monoclonal antibodies. However, part of the increased 
adhesion is also dependent on increased expression of 
CDl lb/CD18.
The CD2+CD3~ lymphocytes that remained detectable in 
the peripheral blood compartment appeared to be C D llb + 
and CD16+, a phenotype characteristic for natural killer 
cells. The ongoing decrease in absolute number of such natu­
ral killer cells between 60 and 1 2 0  minutes after the first
OKT3 administration might be caused by a release of in- 
terIeukin-2 , which is known to occur within 2  hours after 
the first dose of 5 mg OKT3 .23,24 Interleukin-2 is able to 
induce an immediate selective disappearance of natural killer 
cells from the peripheral blood ,25 as can be explained by an 
increased adhesion of these cells to endothelium as was 
shown by in vitro studies.25'27 In contrast, administration of 
methylprednisolone did not induce a disappearance, but a 
transient increase of CDl lb +C D 2f cells, followed by a grad­
ual, mild decrease, as described previously.2*'29
The persistence of lymphocytopenia after administration 
of OKT3 (or other anti-CD3 monoclonal antibodies of the 
IgG2a isotype) may be caused by at least two possibly coop­
erating mechanisms; It may result from opsonization of T 
lymphocytes by OKT3 and complement, followed by se­
questration of such sensitized lymphocytes in the mononu­
clear phagocyte system. Alternatively, it may result from 
upregulation of VCAM-1 and ICAM-1 on the endothelium, 
as induced by cytokines like tumor necrosis factor a and 
interferon y, which are known to be released following 
OKT3 administration23,24 and which may lead to increased 
adhesiveness of the endothelium for its counterstructures 
CD49d/CD29 and CDlla/CD18 or CDl lb/CD 18, respec­
tively, expressed on peripheral blood lymphocytes.30'31 Evi­
dence for upregulation of VCAM-1 by CD3 monoclonal 
antibodies was provided by Bergese et al34 after administra­
tion of the hamster monoclonal antibody 145-2C11 in mice.
Because the murine IgA isotype switch variant CD3 
monoclonal antibody does not bind to human Fc receptors, 
does not induce complement activation, and hardly results 
in release of cytokines, administration in vivo of IgA anti- 
CD 3 antibody does not lead to persistent lymphocytopenia.*^
In conclusion, we provide evidence that on administration 
of CD3 monoclonal antibodies in vivo, the immediate pe­
ripheral blood lymphocytopenia is, at least partly, explained 
by changes in the expression of adhesion molecules on the 
surface of T lymphocytes, leading to increased adhesiveness 
of these cells to vascular endothelium.
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